Terms: = Ovarian cancer AND CTCF, P49711, 10664, ENSG00000102974
25 results:
1. RPL35A drives ovarian cancer progression by promoting the binding of YY1 to ctcf promoter.
Wu H; Xia L; Sun L; Li D; Liu X; Song H; Sheng J; Wang K; Feng Q
J Cell Mol Med; 2024 Mar; 28(6):e18115. PubMed ID: 38436544
[TBL] [Abstract] [Full Text] [Related]
2. ctcfL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy.
Salgado-Albarrán M; Späth J; González-Barrios R; Baumbach J; Soto-Reyes E
NPJ Syst Biol Appl; 2022 Feb; 8(1):5. PubMed ID: 35132075
[TBL] [Abstract] [Full Text] [Related]
3. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer.
Nakamura K; Reid BM; Chen A; Chen Z; Goode EL; Permuth JB; Teer JK; Tyrer J; Yu X; Kanetsky PA; Pharoah PD; Gayther SA; Sellers TA; Lawrenson K; Karreth FA
Am J Hum Genet; 2022 Jan; 109(1):116-135. PubMed ID: 34965383
[TBL] [Abstract] [Full Text] [Related]
4. Predicting pathogenic non-coding SVs disrupting the 3D genome in 1646 whole cancer genomes using multiple instance learning.
Nieboer MM; Nguyen L; de Ridder J
Sci Rep; 2021 Jul; 11(1):14411. PubMed ID: 34257393
[TBL] [Abstract] [Full Text] [Related]
5. Tales from topographic oceans: topologically associated domains and cancer.
Campbell MJ
Endocr Relat Cancer; 2019 Nov; 26(11):R611-R626. PubMed ID: 31505466
[TBL] [Abstract] [Full Text] [Related]
6.
Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
[TBL] [Abstract] [Full Text] [Related]
7. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
[TBL] [Abstract] [Full Text] [Related]
8. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
Zhao J; Wang Y; Liang Q; Xu Y; Sang J
J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
[TBL] [Abstract] [Full Text] [Related]
9. Novel ctcf mutations in Chinese patients with ovarian endometriosis.
Guo J; Cao B; Xu X; Wu F; Zhu B
Mol Med Rep; 2018 Jul; 18(1):1031-1036. PubMed ID: 29845264
[TBL] [Abstract] [Full Text] [Related]
10. Transcription factor profiling reveals molecular choreography and key regulators of human retrotransposon expression.
Sun X; Wang X; Tang Z; Grivainis M; Kahler D; Yun C; Mita P; Fenyö D; Boeke JD
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5526-E5535. PubMed ID: 29802231
[TBL] [Abstract] [Full Text] [Related]
11. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).
Mitamura T; Pradeep S; McGuire M; Wu SY; Ma S; Hatakeyama H; Lyons YA; Hisamatsu T; Noh K; Villar-Prados A; Chen X; Ivan C; Rodriguez-Aguayo C; Hu W; Lopez-Berestein G; Coleman RL; Sood AK
Oncogene; 2018 Feb; 37(6):722-731. PubMed ID: 29059175
[TBL] [Abstract] [Full Text] [Related]
12. A novel somatic MAPK1 mutation in primary ovarian mixed germ cell tumors.
Zou Y; Deng W; Wang F; Yu XH; Liu FY; Yang BC; Huang MZ; Guo JB; Xie QH; He M; Huang OP
Oncol Rep; 2016 Feb; 35(2):725-30. PubMed ID: 26548627
[TBL] [Abstract] [Full Text] [Related]
13. Patterns of ctcf and ZFHX3 Mutation and Associated Outcomes in Endometrial cancer.
Walker CJ; Miranda MA; O'Hern MJ; McElroy JP; Coombes KR; Bundschuh R; Cohn DE; Mutch DG; Goodfellow PJ
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26330387
[TBL] [Abstract] [Full Text] [Related]
14. Histone h1.3 suppresses h19 noncoding RNA expression and cell growth of ovarian cancer cells.
Medrzycki M; Zhang Y; Zhang W; Cao K; Pan C; Lailler N; McDonald JF; Bouhassira EE; Fan Y
Cancer Res; 2014 Nov; 74(22):6463-73. PubMed ID: 25205099
[TBL] [Abstract] [Full Text] [Related]
15. Hypomethylation of the ctcfL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
[TBL] [Abstract] [Full Text] [Related]
16. BORIS/ctcfL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
Link PA; Zhang W; Odunsi K; Karpf AR
Cancer Immun; 2013; 13():6. PubMed ID: 23390377
[TBL] [Abstract] [Full Text] [Related]
17. Disruption of ctcf at the miR-125b1 locus in gynecological cancers.
Soto-Reyes E; González-Barrios R; Cisneros-Soberanis F; Herrera-Goepfert R; Pérez V; Cantú D; Prada D; Castro C; Recillas-Targa F; Herrera LA
BMC Cancer; 2012 Jan; 12():40. PubMed ID: 22277129
[TBL] [Abstract] [Full Text] [Related]
18. BORIS in human cancers -- a review.
Martin-Kleiner I
Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
[TBL] [Abstract] [Full Text] [Related]
19. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/ctcf expression ratio and advanced stage.
Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
[TBL] [Abstract] [Full Text] [Related]
20. BORIS/ctcfL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells.
Renaud S; Loukinov D; Alberti L; Vostrov A; Kwon YW; Bosman FT; Lobanenkov V; Benhattar J
Nucleic Acids Res; 2011 Feb; 39(3):862-73. PubMed ID: 20876690
[TBL] [Abstract] [Full Text] [Related]
[Next]
